Edinburgh Genomics Pioneering Research to Tackle Liver Damage and Type II Diabetes
Edinburgh Genomics is involved with a large-scale initiative led by Eagle Genomics and the Stratified Medicine Scotland Innovation Centre (SMS-IC).
The project will lead ground-breaking research that could help to develop diagnostic tests and treatments for patients with non-alcoholic fatty liver disease (NAFLD).
NAFLD leads to a build-up of excessive fat in the liver that can lead to liver damage in people who do not drink heavily.
The disorder affects 25% of the world’s population and is strongly linked to type II diabetes.
Miles Briggs, Scottish Conservative Health Spokesman, comments:
“This is an incredibly worthwhile piece of research that harnesses the knowledge and capabilities of Edinburgh Genomics Research team.
“This piece of research could reduce the number of people developing type II diabetes and have a huge positive impact on millions of Scots.”